Oracle (ORCL) ($33.21) reported disappointing quarterly results after the close on Thursday, but also announced that they will raise its dividend by 100%, and will implement a $12 billion share buyback program. The company will also shift its listing to the NYSE from the Nasdaq. The stock ended Thursday just above its 200-day SMA at $33.13, but opened below my annual value level, now a pivot at $30.81. The stock has recently been downgraded to hold from buy according to ValuEngine with a quarterly value level at $27.81, an annual pivot at $30.81, a semiannual pivot at $31.89 and annual risky level at $34.68.
Teva Pharmaceutical (TEVA) ($38.88) received FDA approval for its Plan B One-Step for use without prescription. The stock ended Thursday just below its 50-day and 200-day SMAs at $38.92 and $39.29, and was little changed at today's open. The stock has had a buy rating according to ValuEngine for more than a year. My monthly value level is $35.89 with a weekly risky level at $40.18.
At the time of publication the author held no positions in any of the stocks mentioned.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV